These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9559787)

  • 1. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
    Mirochnick M; Capparelli E; Dankner W; Sperling RS; van Dyke R; Spector SA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):808-12. PubMed ID: 9559787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
    Moore KH; Raasch RH; Brouwer KL; Opheim K; Cheeseman SH; Eyster E; Lemon SM; van der Horst CM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2732-7. PubMed ID: 8593010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of zidovudine in infants: a population analysis across studies.
    Mirochnick M; Capparelli E; Connor J
    Clin Pharmacol Ther; 1999 Jul; 66(1):16-24. PubMed ID: 10430105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates.
    Wei L; Mansoor N; Khan RA; Czejka M; Ahmad T; Ahmed M; Ali M; Yang DH
    Biopharm Drug Dispos; 2019 Nov; 40(9):341-349. PubMed ID: 31693190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.
    Morse GD; Portmore AC; Marder V; Plank C; Olson J; Taylor C; Bonnez W; Reichman RC
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2245-52. PubMed ID: 1444306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerance of zidovudine in preterm infants.
    Capparelli EV; Mirochnick M; Dankner WM; Blanchard S; Mofenson L; McSherry GD; Gay H; Ciupak G; Smith B; Connor JD;
    J Pediatr; 2003 Jan; 142(1):47-52. PubMed ID: 12520254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.
    Cañas E; Pachon J; Garcia-Pesquera F; Castillo JR; Viciana P; Cisneros JM; Jimenez-Mejias ME
    Antimicrob Agents Chemother; 1996 Jan; 40(1):230-3. PubMed ID: 8787912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
    Vanhove GF; Kastrissios H; Gries JM; Verotta D; Park K; Collier AC; Squires K; Sheiner LB; Blaschke TF
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2428-32. PubMed ID: 9371345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Bogner JR; Notheis G; Goebel FD; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1997 May; 41(5):1143-5. PubMed ID: 9145885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.
    Stretcher BN; Pesce AJ; Frame PT; Stein DS
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1541-7. PubMed ID: 7979286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.
    Capparelli EV; Englund JA; Connor JD; Spector SA; McKinney RE; Palumbo P; Baker CJ
    J Clin Pharmacol; 2003 Feb; 43(2):133-40. PubMed ID: 12616665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.
    Fauchet F; Treluyer JM; Frange P; Urien S; Foissac F; Bouazza N; Benaboud S; Blanche S; Hirt D
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4801-8. PubMed ID: 23877688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.
    Robbins BL; Rodman J; McDonald C; Srinivas RV; Flynn PM; Fridland A
    Antimicrob Agents Chemother; 1994 Jan; 38(1):115-21. PubMed ID: 7511360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant.
    Kenyon CF; Knoppert DC; Lee SK; Vandenberghe HM; Chance GW
    Antimicrob Agents Chemother; 1990 Feb; 34(2):265-8. PubMed ID: 2327775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
    Aweeka FT; Gambertoglio JG; van der Horst C; Raasch R; Jacobson MA
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1773-8. PubMed ID: 1416864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate.
    Lopez-Anaya A; Unadkat JD; Schumann LA; Smith AL
    J Acquir Immune Defic Syndr (1988); 1990; 3(11):1052-8. PubMed ID: 2120418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
    Brockmeyer NH; Tillmann I; Mertins L; Barthel B; Goos M
    Eur J Med Res; 1997 Sep; 2(9):377-83. PubMed ID: 9300934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.